| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| FMR LLC | 10% | +7.8% | $414,340,651 | +$32,457,883 | 13,132,826 | +8.5% | FMR LLC | 29 Aug 2025 |
| JANUS HENDERSON GROUP PLC | 10% | -12% | $472,013,392 | -$57,168,819 | 13,104,203 | -11% | JANUS HENDERSON GROUP PLC | 30 Sep 2025 |
| RA CAPITAL MANAGEMENT, L.P. | 9.9% | $426,531,754 | 12,964,491 | RA Capital Management, L.P. | 31 Mar 2025 | |||
| T. Rowe Price Investment Management, Inc. | 8.6% | +37% | $520,196,135 | +$137,268,465 | 11,296,333 | +36% | T. Rowe Price Investment Management, Inc. | 31 Dec 2025 |
| BlackRock, Inc. | 7.6% | $323,263,490 | 9,825,638 | BlackRock, Inc. | 31 Mar 2025 |
As of 31 Dec 2025, 289 institutional investors reported holding 147,535,349 shares of Vaxcyte, Inc. - COMMON STOCK (PCVX). This represents 112% of the company’s total 131,352,709 outstanding shares.
The largest institutional shareholders of Vaxcyte, Inc. - COMMON STOCK (PCVX) together control 90% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| FMR LLC | 11% | 13,834,514 | +11% | 0.03% | $638,324,485 |
| JANUS HENDERSON GROUP PLC | 10% | 13,387,188 | +2.2% | 0.28% | $617,730,753 |
| VANGUARD GROUP INC | 9.3% | 12,193,986 | -1% | 0.01% | $562,630,515 |
| T. Rowe Price Investment Management, Inc. | 8.6% | 11,296,333 | +36% | 0.33% | $521,213,000 |
| RA CAPITAL MANAGEMENT, L.P. | 8.2% | 10,724,599 | -10% | 5.1% | $494,832,998 |
| BlackRock, Inc. | 7.8% | 10,246,378 | +2.9% | 0.01% | $472,767,877 |
| WELLINGTON MANAGEMENT GROUP LLP | 4.5% | 5,966,310 | +19% | 0.05% | $275,285,543 |
| STATE STREET CORP | 3.8% | 4,980,005 | +4.1% | 0.01% | $229,777,431 |
| Paradigm Biocapital Advisors LP | 3.1% | 4,068,020 | +7.5% | 5% | $187,698,443 |
| Deep Track Capital, LP | 3% | 4,000,000 | +33% | 4.2% | $184,560,000 |
| D. E. Shaw & Co., Inc. | 2.8% | 3,631,053 | -15% | 0.13% | $167,536,785 |
| WESTFIELD CAPITAL MANAGEMENT CO LP | 2.7% | 3,539,717 | -5.2% | 0.68% | $163,322,542 |
| Kynam Capital Management, LP | 2.2% | 2,922,335 | -4.9% | 8.8% | $134,836,537 |
| GEODE CAPITAL MANAGEMENT, LLC | 2.2% | 2,866,305 | -0.61% | 0.01% | $132,271,037 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 1.3% | 1,725,000 | +418% | 0.12% | $79,591,500 |
| Caligan Partners LP | 1.3% | 1,704,815 | 7.2% | $78,660,164 | |
| Polar Capital Holdings Plc | 1.3% | 1,672,783 | +303% | 0.35% | $77,182,208 |
| Pivotal bioVenture Partners Investment Advisor LLC | 1% | 1,372,425 | 0% | 24% | $63,323,690 |
| MAVERICK CAPITAL LTD | 1% | 1,354,237 | +5% | 0.67% | $62,484,495 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 0.99% | 1,293,830 | +0.03% | 0.01% | $59,697,316 |
| NORGES BANK | 0.94% | 1,228,939 | 0.01% | $56,703,245 | |
| Eversept Partners, LP | 0.91% | 1,197,722 | -16% | 3.1% | $55,262,893 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 0.89% | 1,175,339 | -30% | 0.01% | $54,232,000 |
| UBS Group AG | 0.83% | 1,093,593 | +29% | 0.01% | $50,458,382 |
| JPMORGAN CHASE & CO | 0.83% | 1,085,519 | -31% | 0% | $50,085,850 |
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2025 Q4 | 147,535,349 | $6,807,145,267 | +$264,435,140 | $46.14 | 289 |
| 2025 Q3 | 141,285,706 | $5,088,913,432 | -$216,599,261 | $36.02 | 282 |
| 2025 Q2 | 147,479,114 | $4,794,596,759 | -$48,097,035 | $32.51 | 292 |
| 2025 Q1 | 133,025,604 | $5,021,104,716 | -$42,905,782 | $37.76 | 302 |
| 2024 Q4 | 140,784,610 | $11,525,526,197 | +$183,138,339 | $81.86 | 318 |
| 2024 Q3 | 136,507,040 | $15,592,116,896 | +$1,498,526,683 | $114.27 | 325 |
| 2024 Q2 | 122,578,572 | $9,264,040,265 | +$268,135,107 | $75.51 | 264 |
| 2024 Q1 | 119,065,967 | $8,130,427,051 | +$1,115,777,265 | $68.31 | 249 |
| 2023 Q4 | 103,087,407 | $6,473,142,685 | +$69,029,370 | $62.80 | 223 |
| 2023 Q3 | 101,381,209 | $5,166,522,410 | +$77,032,504 | $50.98 | 202 |
| 2023 Q2 | 99,996,517 | $4,993,540,992 | +$865,860,362 | $49.94 | 194 |
| 2023 Q1 | 84,121,058 | $3,152,798,116 | +$159,886,756 | $37.48 | 186 |
| 2022 Q4 | 81,609,487 | $3,913,093,743 | +$1,140,362,544 | $47.95 | 197 |
| 2022 Q3 | 56,496,728 | $1,356,264,990 | +$122,059,625 | $24.00 | 121 |
| 2022 Q2 | 51,432,581 | $1,119,137,255 | +$31,274,087 | $21.76 | 103 |
| 2022 Q1 | 49,852,918 | $1,203,855,921 | +$69,029,421 | $24.15 | 86 |
| 2021 Q4 | 44,718,114 | $1,063,493,543 | +$32,023,661 | $23.79 | 84 |
| 2021 Q3 | 43,198,231 | $1,095,966,337 | -$195,558 | $25.37 | 77 |
| 2021 Q2 | 43,222,434 | $972,744,067 | -$14,050,462 | $22.51 | 74 |
| 2021 Q1 | 44,022,105 | $869,193,186 | +$26,485,491 | $19.75 | 73 |
| 2020 Q4 | 42,260,768 | $1,118,933,017 | +$58,331,379 | $26.57 | 83 |
| 2020 Q3 | 37,761,937 | $1,857,382,730 | +$103,777,823 | $49.38 | 60 |
| 2020 Q2 | 35,950,832 | $1,126,753,000 | +$1,126,753,000 | $31.61 | 38 |